Interferons: 
Antiangiogenesis agents 
(a reasonable theory)

JOSEPH G SINKOVICS, MD, FACP

JG SINKOVICS. Interferons: Antiangiogenesis agents (a reasonable theory). Can J Infect Dis 1992;3 (Suppl B):128B-132B. Antiviral and immunomodulatory effects of interferons (IFNs) are well-known. This communication lists arguments for explicit antiangiogenetic effects exerted by interferons. There is strong likelihood that IFNs α, β and γ inhibit the int family of genes whose gene product proteins are the acidic and basic fibroblast growth factors. Some of these growth factors promote the growth of vascular endothelial cells. IFN-α inhibits basic, and IFN-γ inhibits acidic fibroblast growth factors. Inhibition of Kaposi sarcoma cell growth is not due to immunological reconstitution of the host. As IFN-α induces clinical remissions but IFN-γ does not, basic and not acidic fibroblast growth factor should be implied as one of the proliferation-inducing factors of Kaposi sarcoma cells. IFNs may interfere with the growth promotional activity of the human immunodeficiency virus Tat protein on Kaposi sarcoma cells. The proliferation of certain melanoma cell populations requires fibroblast growth factors. If this mechanism is mediated through amplified int genes, IFNs may be active clinically in this subset of melanomas. Some breast carcinoma cells induce neovascularization and metastasize. If this activity is mediated through amplified int genes, IFNs may be active clinically in this subset of breast carcinomas.

Key Words: Angiogenesis, Antiangiogenesis, Human immunodeficiency virus-tat, Interferons, Interleukins, Proto-oncogenes int-int, Transforming growth factor-β

Interférons: agents anti-angiogénèse (théorie plausible)
Les effets antiviraux et immuno-modulateurs des interférons (IFN) sont bien connus. Le présent document énumère les arguments à l’appui des effets anti-angiogénétiques explicites qu’exercent les interférons. Tout porte à croire que les interférons α, β et γ inhibent la famille int des gènes dont les produits protéiques sont les facteurs de croissance fibroblastiques acides et basiques. Certains de ces facteurs de croissance favorisent la croissance des cellules endothéliales vasculaires. L’IFN-α inhibe les facteurs basiques et l’IFN-γ inhibe les facteurs de croissance fibroblastiques acides. L’inhibition de la croissance des cellules du sarcome de Kaposi n’est pas attribuable à la reconstitution immunologique de l’hôte. Comme l’IFN-α induit des rémissions cliniques contrairement à l’IFN-γ, les facteurs de croissance fibroblastiques basiques et non pas les facteurs acides, doivent être soupçonnés d’induire la prolifération des cellules du sarcome de Kaposi. Les IFN peuvent interférer avec l’activité des protéines VIH-Tat qui favorisent la croissance des cellules du sarcome de Kaposi. La prolifération de certaines populations de cellules de mélanomes requiert la participation des facteurs de croissance fibroblastiques. Si ce mécanisme est modulé par le recours à des gènes int amplifiés, les IFN peuvent se révéler cliniquement actifs dans ce sous-groupe de cancers du sein.
A recent report describes successful treatment of pulmonary hemangioma in a 12-year-old boy with human recombinant interferon-α2a (Hu-r-IFN-α2a) (1). An enthusiastic editorial reviews tumour-induced angiogenesis and its agonists and antagonists (2). Neither of these articles mentions important animal data. Sidky and Borden (3) showed that murine and human IFN-β inhibited tumour-induced angiogenesis in species-specific fashion and IFNs α, β and γ also inhibited lymphocyte-induced angiogenesis. They proposed that IFNs suppressed the release of certain (not all) angiogenesis-inducing factors from tumour cells and lymphocytes, even when IFNs exerted no inhibitory effect on the replication of the tumour cells or lymphocytes (3).

Based on this work, the author proposed (in the plenary lecture on Kaposi's sarcoma at the 14th International Cancer Congress in 1986) that IFN-α suppressed the growth of acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma by directly antagonizing angiogenesis and not indirectly by restoring immunocompetence (4). Data on the possible restoration of immunocompetence in AIDS by IFN treatment remain inconclusive. As recently as 1988, statements like this appear: "...no significant changes in immunological function were noted during treatment with IFN-α; peripheral blood CD4 percentages, natural killer cell number and activity, and antigen- and mitogen-induced blast transformation were essentially unchanged" (5). It appears that patients with high pretreatment CD4 cell counts respond best to IFN (6).

A response rate of 45% was observed in patients with AIDS-Kaposi's sarcoma circulating more than 400 CD4 cells/mm³ (7). Patients with high endogenous acid labile IFN-α levels do not respond (8). Even though Hu-r-IFN-α2a and b reduce human immunodeficiency virus-1 (HIV-1) levels in AIDS (decreased number of isolates from blood lymphocytes and decreased circulating HIV p24 antigen level) (5,6), this virus is not directly involved in the induction of Kaposi's sarcoma in AIDS. Thus, the antiretroviral effect of IFN-α should not directly influence the growth of Kaposi's sarcoma cells.

In analyzing the mechanism of action in AIDS-Kaposi's sarcoma, a direct growth inhibitory effect of IFNs on endothelial cells was proposed (4,9). IFN-β also induces remissions of AIDS-Kaposi's sarcoma (10). IFN-γ exerts a strong inhibitory effect on the growth of vascular endothelial cells in vitro and acts antagonistically to alpha endothelial cell growth factor (acidic fibroblast growth factor) which induces proliferation of endothelial cells (11). However, in a few clinical trials, IFN-γ acted in AIDS-Kaposi's sarcoma as a weak antiangiogenesis agent (4,12) or it failed to stop progression of disease entirely (10).

If the pathogenesis of AIDS-Kaposi's sarcoma is envisioned properly, the first stimulus derives from retrovirus-infected T4 cells (13-15). The as yet undefined molecular mediators thus generated induce multifocal growth of endothelial cells. Prominent among these molecular mediators is the tat protein - Tat. This protein promoted the growth of AIDS-Kaposi's sarcoma cells in culture; this activity was neutralized by antibody directed against Tat (16,17). Furthermore, IFN-α activates the 2',5' oligoadenylate synthetase system (18). The Tat protein blocks this enzyme system when it binds to Tar encoded by HIV-tar, another activator of this enzyme (19). Thus, IFN-α antagonizes Tat by activating an enzyme system that Tat blocks. Therefore, one of the antiangiogenesis effects of IFN-α rests on its antagonism with Tat over the 2',5' oligoadenylate synthetase system.

A second stimulus for the growth of AIDS-Kaposi's sarcoma cells is the angiogenesis-inducing factors from tumour cells and lymphocytes, even when IFNs exerted no inhibitory effect on the replication of the tumour cells or lymphocytes (3).
TABLE 2
Promotion of growth and regression of AIDS-Kaposi’s sarcoma (KS) cells: Proposed mechanisms

<table>
<thead>
<tr>
<th>Promotion</th>
<th>Regression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inducing factor(s) derived from HIV-infected T4 cells (14) bFGF-like molecular mediators derived from KS cells (20)</td>
<td>IFNα suppresses genes or gene product proteins of int family* (9)</td>
</tr>
<tr>
<td>IL-6 and IL-6R expression by KS cells for autocrine growth (24)</td>
<td>IFNα activates Tar and 2',5' oligoadenylate synthetase thus antagonizing Tat, the inhibitor of this system (19)</td>
</tr>
<tr>
<td>Anti-IFNs and IFN-inactivators (including endogenous acid-labile IFNα) (8)</td>
<td>TGFβ switched off* (by mechanism unknown; another possible action of IFNα? ) with consequential cessation of IL-6, PDGF and IL-1 antagonist protein production</td>
</tr>
<tr>
<td>TGFβ production by KS cells (15) antagonizing IL-2 and TNFα, β; stimulating IL-6 and PDGF production; inducing IL-1R antagonist protein production (42-44)</td>
<td>IL-1 production* arresting growth of endothelial cells by reducing bFGF-R expression (45)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Some of these mechanisms of action are only proven in part or are not yet proven experimentally but are logical consequences of interactions that have been proven experimentally. HIV Human immunodeficiency virus; IFN Interferon; IL (R) Interleukin (receptor); PDGF Platelet-derived growth factor; TGF Transforming growth factor

situ hybridization (21). This gene family thus may be another target of antiangiogenesis effect by interferons.

The fact that IFN-γ, a natural antagonist of aFGF (endothelial cell growth factor-α), failed to induce remissions in AIDS-Kaposi’s sarcoma indicates that the natural driving force of Kaposi’s sarcoma cell proliferation is not aFGF because it was, IFN-γ should also have induced remission. The receptor for aFGF possesses tyrosine kinase activity and is encoded by an fms-like gene (22). Table 1 provides an oversimplified account of the effect of growth factors on vascular endothelial cells including those of Kaposi’s sarcoma (9).

Another growth factor prominently active in these cells is interleukin (IL)-6. AIDS-Kaposi’s sarcoma cells produce IL-6 and express IL-6 receptors; thus, they may use IL-6 as an autocrine growth factor (24). There is a complex interaction of growth factors and their inhibitors affecting angiogenesis in general. For example, IL-1 antagonizes bFGF-receptor expression on endothelial cells and thus breaks the autocrine growth advantage of these cells based on bFGF production. Transforming growth factor-beta (TGF-β) is an antagonist of IL-1 receptor expression while it induces angiogenesis in the chorioallantois membrane of the chicken embryo. This substance is inhibitory to lymphocyte-mediated cytotoxicity and probably acts as a natural antagonist of IL-2. Macrophages of HIV-1-infected patients release TNF-α and IL-1β. IL-4 antagonizes the secretion of tumour necrosis factor-alpha (TNF-α), IL-1β and IL-6 by monocytes (25). Growth factors acting promotionally on AIDS-Kaposi’s sarcoma cells are the Tat protein, K-bFGF, IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF), platelet-derived growth factor and the combination of IL-2 and IFN-β (Table 2) (25). Locally acting immunosuppressive factors further promoting the growth of these cells are TGF-β, anti-interferons and probably arachidonic acid-derived prostaglandins. These lesions regress under treatment with IFN-α antagonizing the effects of Tat and/or deactivating the K-FGF proto-oncogene (Table 2). Apoptosis of abnormal endothelial cells may ensue under the effects of IFN-α or TNF-α or β (lymphotoxin) (23). These latter factors may derive from defensive monocytes-macrophages or T8 lymphocytes and act simultaneously with the cessation of TGF-β production (Table 2) (25).

EFFECTS IN OTHER TUMOUR SYSTEMS

Activation of the int-int proto-oncogene family occurs in malignant melanoma but without overt and excessive neovascularization (26,27). Yet a subset of these tumours respond to treatment with IFNs (28). In breast carcinoma, neovascularization in a subset of primary tumours correlates with their metastatic potential (29). It is not known which proto-oncogene is amplified to encode angiogenetic growth factors in breast carcinoma. It is known that in a subset of human breast carcinomas, the int family of proto-oncogenes is amplified (30), as it is amplified in murine mammary tumour virus-induced breast carcinomas (31). While IFN did not inhibit the replication of this murine tumour virus, it reduced its oncogenicity (32). It is essential to find out if the subset of breast carcinomas which induce neovascularization possesses amplified int and responds to treatment with IFN, and if IFN could thus prevent the formation of metastases in these subsets of human breast carcinomas. While the majority of melanomas and breast carcinomas fail to respond to IFNs, a small subset do respond. This author proposes that the responsive subset of these tumours operates through activated int family genes and fibroblast growth factors promote their growth. Deactivation of int genes by IFNs could be the mechanism of growth inhibition. However, the actual studies showing such correlation have not as yet been concluded.

Astrocytomas, particularly glioblastoma multiforme, induce excessive neovascularization (33). Treatment with IFN-α results in significant reduction of neovascularization (34). Antitumoral effects of IFNs in these
systems may be based on deactivation of the \textit{int} protooncogenes.

While a refined action such as growth factor gene inhibition may be the major effect of IFNs on proliferating vascular endothelial cells, in a virally induced murine leukemia-tumour system, IFN-\(\alpha\) induced necrosis of vascular endothelial cells (35). This effect is similar to that of TNF-\(\alpha\), known to elicit programmed cell death (apoptosis) of vascular endothelial cells (23).

IFN-\(\alpha\) and \(\beta\) downregulate the expression of mitochondrial genes for cytochrome b and c oxidase and a dehydrogenase (subunit 5 but not subunit 6) system. Cycloheximide inhibited this effect, thus implying the activation of an IFN-responsive gene(s) that encodes the synthesis of products with the capability to suppress genes or mRNA for the mitochondrial enzyme systems listed above (36). It is not yet understood how these novel effects of IFNs may affect tumour growth or angiogenesis.

**INHIBITORS OF ANGIOGENESIS OTHER THAN INTERFERONS**

In addition to the classical combination of heparin and corticosteroids (37,38), fumagillin antibiotics (fumagillin) exert strong inhibitory effect on neovascularization and thus suppress metastasis formation by murine tumours (39). Krestin, the mycelial polysaccharide of \textit{Coriolus versicolor}, is a strong inhibitor of tumour-induced angiogenesis (40). Human recombinant platelet factor 4 and its analogues emerge as potent natural inhibitors of angiogenesis (41).

**SUMMARY**

Combinations of lymphokines, monokines, cytokines and growth factor inhibitors antagonistic to neovascularization have been identified and developed. Kaposi's sarcoma provides an excellent in vitro and in vivo model system for the study of angiogenesis inhibitors. Inhibitors of tumour-induced neovascularization thus identified may be of great clinical value in suppressing the growth and metastasis formation of highly malignant tumours.

**REFERENCES**
